TenNor Therapeutics (Suzhou) Limited (HKG:6872)

HKG:6872 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Operating Income Operating Income Growth	-136.56	-119.16	-78.01	-123.2
Net Income Net Income Growth	-139.32	-153.24	-145.93	-191.84
Earnings Per Share EPS Growth	-3.31	-3.85	-3.89	-5.19
EPS Growth	-	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Investments Cash & Investments Growth	714.73	183.77	97.82	58.11
Total Debt Total Debt Growth	64.24	28.65	53.02	59.42
Net Cash (Debt) Net Cash Growth	650.49	155.11	44.79	-1.31
Net Cash Growth	-	246.28%	-	-
Net Cash Per Share Net Cash Per Share Growth	15.44	3.89	1.19	-0.04

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Operating Cash Flow Operating Cash Flow Growth	-106.43	-87.2	-48.6	-98.12
Capital Expenditures CapEx Growth	-0.8	-0.23	-0.2	-0.4
Free Cash Flow Free Cash Flow Growth	-107.23	-87.42	-48.8	-98.51
Free Cash Flow Growth	-	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 1, 2026

Data Sources Report a data error